KR20130003394A - Correction method of cellulite - Google Patents
Correction method of cellulite Download PDFInfo
- Publication number
- KR20130003394A KR20130003394A KR1020110064727A KR20110064727A KR20130003394A KR 20130003394 A KR20130003394 A KR 20130003394A KR 1020110064727 A KR1020110064727 A KR 1020110064727A KR 20110064727 A KR20110064727 A KR 20110064727A KR 20130003394 A KR20130003394 A KR 20130003394A
- Authority
- KR
- South Korea
- Prior art keywords
- fat
- cellulite
- correction method
- skin
- obesity
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 47
- 208000035484 Cellulite Diseases 0.000 title claims abstract description 25
- 206010049752 Peau d'orange Diseases 0.000 title claims abstract description 25
- 230000036232 cellulite Effects 0.000 title claims abstract description 25
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 28
- 229940079593 drug Drugs 0.000 claims abstract description 27
- 229910002092 carbon dioxide Inorganic materials 0.000 claims abstract description 15
- 239000001569 carbon dioxide Substances 0.000 claims abstract description 14
- 210000001015 abdomen Anatomy 0.000 claims abstract description 10
- 210000000689 upper leg Anatomy 0.000 claims abstract description 10
- 244000309466 calf Species 0.000 claims abstract description 6
- 238000007599 discharging Methods 0.000 claims abstract description 6
- 230000002040 relaxant effect Effects 0.000 claims abstract description 4
- 238000002347 injection Methods 0.000 claims description 20
- 239000007924 injection Substances 0.000 claims description 20
- 208000008589 Obesity Diseases 0.000 claims description 18
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 18
- 235000020824 obesity Nutrition 0.000 claims description 18
- 230000004130 lipolysis Effects 0.000 claims description 15
- 230000017531 blood circulation Effects 0.000 claims description 10
- 230000000638 stimulation Effects 0.000 claims description 10
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 9
- 210000000577 adipose tissue Anatomy 0.000 claims description 9
- 229960001476 pentoxifylline Drugs 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 8
- 210000003205 muscle Anatomy 0.000 claims description 7
- OWYLAEYXIQKAOL-UHFFFAOYSA-N 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone Chemical compound COC1=CC(OC)=CC(OC)=C1C(=O)CCCN1CCCC1 OWYLAEYXIQKAOL-UHFFFAOYSA-N 0.000 claims description 6
- 229960001415 buflomedil Drugs 0.000 claims description 6
- 239000000835 fiber Substances 0.000 claims description 6
- 230000002366 lipolytic effect Effects 0.000 claims description 6
- BBBFJLBPOGFECG-UHFFFAOYSA-N salmon calcitonin Chemical compound C=1N=CNC=1CC(C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(C(C)O)C(=O)NC(CC=1C=CC(O)=CC=1)C(=O)N1C(CCC1)C(=O)NC(CCCNC(N)=N)C(=O)NC(C(C)O)C(=O)NC(CC(N)=O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N1C(CCC1)C(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(C(C)C)NC(=O)C1CSSCC(N)C(=O)NC(CO)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)N1 BBBFJLBPOGFECG-UHFFFAOYSA-N 0.000 claims description 6
- 206010030113 Oedema Diseases 0.000 claims description 5
- 230000007246 mechanism Effects 0.000 claims description 5
- 108010032809 mucopolysaccharidase Proteins 0.000 claims description 5
- 210000000617 arm Anatomy 0.000 claims description 4
- 210000002808 connective tissue Anatomy 0.000 claims description 4
- 230000004089 microcirculation Effects 0.000 claims description 4
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 claims description 3
- HBGOLJKPSFNJSD-UHFFFAOYSA-N Etamsylate Chemical compound CC[NH2+]CC.OC1=CC=C(O)C(S([O-])(=O)=O)=C1 HBGOLJKPSFNJSD-UHFFFAOYSA-N 0.000 claims description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 3
- 244000194101 Ginkgo biloba Species 0.000 claims description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 3
- 230000005856 abnormality Effects 0.000 claims description 3
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims description 3
- 229960003556 aminophylline Drugs 0.000 claims description 3
- 229960001948 caffeine Drugs 0.000 claims description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229960004194 lidocaine Drugs 0.000 claims description 3
- 229960004919 procaine Drugs 0.000 claims description 3
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 238000002690 local anesthesia Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 230000037394 skin elasticity Effects 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 230000008859 change Effects 0.000 abstract description 2
- 230000003313 weakening effect Effects 0.000 abstract 1
- 239000003925 fat Substances 0.000 description 46
- 210000003491 skin Anatomy 0.000 description 16
- 210000001789 adipocyte Anatomy 0.000 description 13
- 238000011282 treatment Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 230000036407 pain Effects 0.000 description 6
- 238000000694 mesotherapy Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000002792 vascular Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 210000004003 subcutaneous fat Anatomy 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 208000031439 Striae Distensae Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H15/00—Massage by means of rollers, balls, e.g. inflatable, chains, or roller chains
- A61H15/02—Massage by means of rollers, balls, e.g. inflatable, chains, or roller chains adapted for simultaneous treatment with light, heat or drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H23/00—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
- A61H23/02—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive
- A61H23/0245—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive with ultrasonic transducers, e.g. piezoelectric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/71—Suction drainage systems
- A61M1/77—Suction-irrigation systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/328—Applying electric currents by contact electrodes alternating or intermittent currents for improving the appearance of the skin, e.g. facial toning or wrinkle treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00452—Skin
- A61B2018/00458—Deeper parts of the skin, e.g. treatment of vascular disorders or port wine stains
- A61B2018/00464—Subcutaneous fat, e.g. liposuction, lipolysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2205/00—Devices for specific parts of the body
- A61H2205/06—Arms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2205/00—Devices for specific parts of the body
- A61H2205/08—Trunk
- A61H2205/083—Abdomen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2205/00—Devices for specific parts of the body
- A61H2205/10—Leg
- A61H2205/106—Leg for the lower legs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2205/00—Devices for specific parts of the body
- A61H2205/10—Leg
- A61H2205/108—Leg for the upper legs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0008—Destruction of fat cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Rehabilitation Therapy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Plastic & Reconstructive Surgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Percussion Or Vibration Massage (AREA)
Abstract
Description
본 발명은 셀룰라이트 교정방법에 관한 것이다The present invention relates to a cellulite correction method
셀룰라이트{cellulite)란 허벅지, 둔부, 아랫배 등과 같은 특정부위 피하지방이 과다하게 쌓여 주머니처럼 뭉치면서 피부가 마치 오렌지 껍질처럼 울퉁불퉁하게 된 상태를 말한다. 즉, 살이 찌고 오랜 시간이 지나면 지방세포들끼리 서로 엉켜붙어 그 주위를 섬유질이 둘러싸게 되고 피하지방층의 지방조직 속에서 수분과 노폐물, 지방이 엉켜 부풀면서 진피의 결합조직을 밀고 올라와 살갖이 오렌지 껍질처럼 울퉁불퉁하게 된다Cellulite (cellulite) refers to a condition in which the subcutaneous fat, such as thighs, buttocks and lower abdomen, is piled up excessively and aggregated like a pocket, and the skin becomes lumpy like an orange peel. In other words, after a long time of fat, fat cells are entangled with each other, so that fibers surround them, and moisture, waste, and fat entangle in the fat tissue of the subcutaneous fat layer, pushing up the connective tissue of the dermis Becomes bumpy like
그의 발생원인은 비만, 호르몬의 불균형, 과도한 술, 담배, 하이힐 착용, 노화, 생리적 피부구조 등이다His causes include obesity, hormonal imbalance, excessive alcohol, tobacco, high heels, aging, and physiological skin structure.
셀룰라이트의 발전 과정은 1단계로 간질울혈, 지방세포, 해리 혈관이 좁아지고, 2 단계는 지방세포 부종, 콜라겐섬유 뭉침, 혈관벽의 더 좁아짐, 3 단계는 지방세포 부종이 심화되고 미세 결절이 발생하고, 4 단계는 미세결절의 뭉침이 생긴다. The development of cellulite is one step, interstitial congestion, adipocytes, dissociated blood vessels are narrowed, the second step is adipocyte edema, agglomeration of collagen fibers, narrower vascular wall, and the third step is intensified fat cell edema and micro nodules. In step 4, agglomeration of micronodules occurs.
상기한 셀룰라이트는 체중이 줄어도 잘 없어지지 않으므로 그 제거가 매우 곤란하다. 종래의 셀룰라이트 제거 방법은, 주무르고, 두둘기고 그리고 꼬집는 방법으로 노폐물을 배출하고 열순환을 촉진시키는 마사지 방법과 고주파 기기를 이용하여 그 열로 심부를 지방 분해하는 방법 그리고 셀룰라이트 크림을 바르는 방법이 있다. The cellulite is difficult to remove even if the weight is reduced, so it is very difficult to remove. Conventional cellulite removal methods include kneading, tapping and pinching to release waste and promote heat circulation, using a high frequency device to fat-depth the core and applying cellulite cream. .
그러나 마사지 및 셀룰라이트 크림도포 방법은 그 효과가 미미하고, 고주파 기기를 사용하는 것 역시 큰 효과를 나타내지 못하고 있는 실정이다
However, the massage and cellulite cream application method is insignificant, and the use of high frequency equipment does not show a great effect.
본 발명을 상기와 같이 제거가 어려운 셀룰라이트를 과학적이고 합리적인 여러가지 단계를 거쳐 매우 효과적으로 제거할 수 있는 방법을 개발하였다
The present invention has developed a method that can effectively remove cellulite that is difficult to remove as described above through various scientific and rational steps.
본 발명의 주요 구성은, 신체의 팔, 복부, 허벅지, 종아리, 전신의 비만 부위를 측정하는 단계; 측정된 비만 부위의 지방분해를 위해, 지방을 둘러싸고 있는 섬유질을 분해하고 지방끼리의 연결고리를 끊어줌으로써 지방을 분해하고 약화시키는 이완처리하는 단계; 비만 부위를 액화이산화탄소를 주사하거나 또는 지방분해 약물을 주사하는 방법 중 어느 하나를 사용하여 지방조직을 분해하는 단계; 분해된 지방을 배출하기 위해, 피부, 지방 및 근육에 대한 강력하고 부드러운 압력을 주어서 지방의 운반과 배출을 돕도록 하는 해체되어 액화된 지방의 배출 단계; 액화되어 배출된 지방을 혈액순환과정과 근육질에서 연소시키기 위해 저주파장비를 사용하여, 전극에 의한 자극으로 지방을 연소시키는 지방연소 단계; 지방이 제거된 비만 부위의 피부 탄력을 향상시키는 단계를 포함하는 것을 특징으로 하며, 상기한 지방분해를 위해 지방을 이완처리하는 단계는 고주파 또는 중저파의 초음파 장치를 이용하여 지방조직을 이완시키는 것을 특징으로 하며, 상기한 비만 부위를 약물 주사로 지방조직을 분해하는 단계에서 사용되는 약물은, 미세혈액순환을 촉진하는 약물로, pentoxifylline, procain, buflomedil, calcitonine2, 수분저류와 부종을 개선하는 약물로, caffein, dicynone, calcitonine, esberiven, thiomucase, 지방분해를 촉진하는 약물로, caffein, pentoxifylline, calcitonine, 결합조직의 이상을 개선하는 약물로 vit C, thiomucase, conjonctil, 국소마취용인 Lidocaine, 혈액순환촉진제인 Ginkgo biloba, 혈액순환촉진 및 지방분해제인 Buflomedil, 지방분해제인 Pentoxifylline, Caffeine, Aminophylline, 분해지방운반제인 L-carnitine 중 3-4 가지 약제를 혼합하여 투여하는 것을 특징으로 하며, 상기한 해체된 지방을 배출시키는 단계는, 하부에 롤러(2)가 구성되고 롤러(2) 사이에는 흡입공(3)을 갖춘 흡입기구(1)를 사용하여, 시술된 비만부위 피부 표면을 흡입시키면서 롤러(2)를 이동시키는 방법으로 실시하는 것을 특징으로 하며, 배출된 지방을 연소시키는 단계는, 5 내지 120 헤르츠의 저주파 장치를 이용하여 피부 표면에 대하여 전기 자극을 실시하는 것을 특징으로 한다
The main configuration of the present invention, measuring the body, arms, abdomen, thighs, calves, obesity of the whole body; Relaxing to decompose and weaken fat by breaking down the fiber surrounding the fat and breaking the link between fats for lipolysis of the measured obesity site; Degrading adipose tissue using any of the methods of injecting liquefied carbon dioxide or a lipolytic drug into the obese site; Discharging the disintegrated and liquefied fat to give strong and gentle pressure to the skin, fat and muscle to assist in the transport and release of fat to release the degraded fat; A fat burning step of burning fat by stimulation by an electrode, using low frequency equipment to burn the liquefied and discharged fat in the blood circulation and muscle; It is characterized in that it comprises the step of improving the skin elasticity of the obese region where the fat is removed, the step of relaxing the fat for the lipolysis is to relax the adipose tissue using a high-frequency or low-frequency ultrasound device The drug used in the step of decomposing adipose tissue by injection of the above-mentioned obesity site is a drug that promotes microcirculation, pentoxifylline, procain, buflomedil, calcitonine2, a drug that improves water retention and edema. , caffein, dicynone, calcitonine, esberiven, thiomucase, a drug that promotes lipolysis, caffein, pentoxifylline, calcitonine, a drug that improves connective tissue abnormalities Ginkgo biloba, Buflomedil for promoting blood circulation and lipolysis, Pentoxifylline for lipolysis, Caffeine, Aminophylline, L-car for dissolving fat It is characterized in that the administration of a mixture of 3-4 medicaments of nitine, the step of discharging the disintegrated fat, the
본 발명에 의하면, 살이 빠져도 쉽게 제거가 어려운 셀룰라이트를 효과적으로 제거할 수 있다According to the present invention, it is possible to effectively remove cellulite that is difficult to remove even if the flesh is lost.
또한 본 발명에 의하면 인체에 통증이 거의 없고 일상 생활에 신체적인 무리가 없이 편리하고 쉽게 셀룰라이트를 제거 가능하다In addition, according to the present invention there is little pain in the human body and can be easily and easily remove cellulite without physical discomfort in daily life.
도 1 는 본 발명의 시술 방법 중 하나인 카복시테라피 방법에 의해 액화이산화탄소 주사 방법으로 지방 조직의 변화를 보여 주는 도면
도 2 는 도 1 의 시술 결과를 예시하는 복부 시술 결과 비교도
도 3 은 본 발명에 따른 방법에서 사용되는 물리기구인 흡입기구(1)를 예시하는 도면1 is a view showing the change of adipose tissue by liquefied carbon dioxide injection method by a carboxytherapy method, one of the treatment method of the present invention
FIG. 2 is a comparison of abdominal procedure results illustrating the procedure result of FIG. 1. FIG.
3 illustrates a suction device 1 which is a physical device used in the method according to the invention.
이하, 본 발명을 보다 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명에서 비만치료에 활용되는 치료법은 아래의 것들을 선택하여 사용한다.Therapies utilized in the treatment of obesity in the present invention select and use the following.
먼저, 중저파 치료법은, 1952년 미국에서 초음파를 공식 물리 치료로 채택한 이래 오늘날 널리 쓰이는 열치료 방법의 하나이다. 최근 20-30 키로헤르츠의 저출력 초음파를 통한 캐비테이션(공동) 현상이 지방분해 및 지방세포 파괴에 효과적이라는 해외 학술자료를 토대로 병원에서 많이 사용되고 있다.First, mid- and low-frequency therapy is one of the thermal treatments that is widely used today since ultrasound was adopted as the official physical therapy in the United States in 1952. Recently, 20-30 kHz cavitation using low-power ultrasound has been widely used in hospitals based on overseas studies that are effective for lipolysis and fat cell destruction.
예를들어 30키로헤르츠의 초음파의 캐비테이션에 의한 작은 기포들이 생성되는데 이 미세 기포들은 초음파의 압축과 이완 주기에 따라 수축과 팽창을 하다가 어느 임계점에 다다르면 내파된다 이렇게 미세 기포가 안에서 파열될 때 기포 내부의 높은 에너지는 높은 압력의 충격으로 발산되면 이 큰 진동이 지방세포의 세포막 주변에서 터지게 되면서 지방조직을 파괴하는 작용을 한다. 또한 이 큰 압력은 지방과 세포간의 공간을 벌려 파괴된 지방이 잘 배출되도록 도와준다For example, small bubbles are generated by ultrasonic cavitation of 30 kilohertz, which contracts and expands according to the compression and relaxation cycles of the ultrasonic wave, and then blasts when they reach a critical point. When the high energy of is released by the impact of high pressure, this large vibration explodes around the cell membranes of fat cells and destroys fat tissue. This large pressure also opens up the space between fat and cells, helping to release the destroyed fat.
다음으로, 고주파(RF) 치료는 30년 전부터 통증치료에 사용되다가 국내 비만클리닉에서 지방분해 효과가 소개되면서 비만 치료법으로 활용되고 있다. 고주파 에너지는 시술부위와 플레이트판(반대편 전극, 접지판)을 이용하여 인체에 통전시키면 전자 활동이 활발히 일어나면서 해당 조직에서 저항이 증가하고 분자 마찰열 방법으로 조직온도 상승시켜 생체열을 발생시킨다Next, radiofrequency (RF) therapy has been used for pain therapy for 30 years, and has been used as a treatment for obesity as lipolysis effects are introduced in domestic obesity clinics. When high-frequency energy is applied to the human body by using a surgical site and a plate plate (opposite electrode, ground plate), electronic activity is active and resistance increases in the tissue, and tissue temperature is raised by molecular friction heat method.
이 열은 특징 부위 동맥과 모세혈관을 확장시켜 혈류량을 4-5배 증가시켜 혈액순환 촉진 효과를 나타낸다. 체온이 섭씨 3-5 도 국소 부위에는 7도 정도 상승되면서 신진대사율이 높아지고 국소적으로 41도 이상이 되면 국소지방조직 용해 효과를 나타내는 것으로 알려져 있다
This heat expands feature areas of arteries and capillaries, increasing blood flow by 4-5 times, which promotes blood circulation. It is known that the body temperature rises about 3-5 degrees Celsius and 7 degrees in the local area, and the metabolic rate increases, and when the temperature rises above 41 degrees, it shows local fatty tissue dissolution effect.
다음으로, 메조테라피(mesotheraphy)방법이 있는데 이는 약물주사 방법으로, 주사깊이에 따라 표피내 주사, 진피표층부 주사, 진피 심층부 주사, 피하내 주사 등과 같이 분류될 수 있다. Next, there is a mesotherapy (mesotheraphy) method, which is a drug injection method, can be classified according to the depth of injection, such as intradermal injection, epidermal layer injection, deep dermal injection, subcutaneous injection and the like.
메소테라피(mesotherapy)란 최근 프랑스에서 도입되어 비만, 미용성형, 노화방지 치료에 탁월한 효과를 나타내는 최신 치료법이다. 각종 질환에 맞는 여러 가지 약물을 메조건(meso-gun : 제조사 무한)(자유로운 주사깊이 조절, 정확한 주입량, 주입량 조절 용이)라는 특수장비를 이용 피부 중간층에 약품을 주입하여 약물에 대한 부작용 및 통증없이 치료하는 방법이다. 주 1 회, 격주, 한달, 단위로 0.1-0.2cc 투입한다. 따라서 메조건을 사용하면 국소부위의 섬유질과 지방세포 분해, 혈관확장과 림프 자극을 통한 소모와 배출, 근육의 인위적 운동 및 자극으로 운동효과가 기대된다Mesotherapy is the latest treatment introduced in France and has an excellent effect on the treatment of obesity, cosmetic surgery and anti-aging. Various drugs suitable for various diseases are injected into the middle layer of the skin using special equipment called meso-gun (manufacturer infinite) (free injection depth control, accurate injection amount, easy adjustment of injection volume), so that there is no side effect and pain on the drug. How to treat it. Add 0.1-0.2cc once a week, every other week, monthly. Therefore, it is expected that the use of meconditioning results in exercise effects due to the breakdown of fibrous and adipocytes in the local area, exhaustion and excretion through vasodilation and lymph stimulation, and artificial movement and stimulation of muscles.
표피내 주사는 피부 표면에서 1mm 정도 깊이 각질층에 약물 흡수하며 약물 흡수가 매우 뛰어나며 통증이 거의 없고 혈종이 생기지 않는다. 진피표층부는 1-2mm, 진피심층부는 2-4mm, 피하내 주사는 4-10mm 깊이로 주사한다Intradermal injection absorbs the drug into the stratum corneum about 1mm deep from the surface of the skin. The drug absorbs very well, has little pain and no hematoma. The dermal layer is 1-2mm, the dermal layer is 2-4mm, the subcutaneous injection is 4-10mm deep.
시술 부위에 따른 시술 방법은 예를들어 아래와 같다The treatment method according to the treatment site is as follows.
팔의 경우, 한쪽 팔에 4-4.5cc 씩 시술하며 팔 안쪽 또는 바깥쪽에 주사바늘 깊이 1-2mm로 혈관을 따라 간격 5mm 정도로 진행한다. 마찬 후 바로 닦아내지 말고 5-10분정도 약물의 건조 및 흡수시간을 주어 마무리한다. 시술 후 결과를 살펴보면 오렌지 스킨 및 사이즈가 감소하고 피부가 유연하고 부드럽게 되었다.In the case of an arm, 4-4.5cc is applied to one arm, and the needle is 1-2mm deep inside or outside the arm and proceeds about 5mm apart along the vessel. Likewise, do not wipe off immediately, but give 5-10 minutes to dry and absorb the drug. After the procedure, the orange skin and size were reduced, and the skin became supple and soft.
허벅지 경우 근육부위를 피하여 허벅지 안쪽 밑 아래쪽을 깊이 4mm로 한쪽 다리에 4-4.5cc씩 시술한다. 시술 후 하지 무거운 느낌 감소하였다. 복부 경우, 갈비뼈가 좌우 "ㅅ"로 갈라지는 부분부터 배꼽 중심으로 좌우 3cm 간격으로 바둑판을 그리듯 주사한다. 옆구리에도 시술시엔 환자를 옆으로 뉘여 주고 한쪽 옆구리 당 3cc 약물 주입한다. In case of thighs, avoid the inner part of the thigh 4-4cc deep to the lower and lower inner thighs. Heaviness in the lower limbs decreased after the procedure. In the case of abdomen, the ribs are injected in a checkerboard at intervals of 3cm from left and right to the center of the navel from the part where the ribs are divided into left and right "ㅅ". In the flanks, the patient lies sideways and injects 3cc of medication per flank.
메조테라피에 사용되는 약물 배합은 미세혈액순환을 촉진하는 약물로, pentoxifylline, procain, buflomedil, calcitonine2를 사용하며, 수분저류와 부종을 개선하는 약물로, caffein, dicynone, calcitonine, esberiven, thiomucase를 사용하며, 지방분해를 촉진하는 약물로, caffein, pentoxifylline, calcitonine를 사용하며, 결합조직의 이상을 개선하는 약물로 vit C, thiomucase, conjonctil을 사용한다. 또한 국소마취용인 Lidocaine, 혈액순환촉진 Ginkgo biloba, 혈액순환촉진 및 지방분해제인 Buflomedil, 지방분해제인 Pentoxifylline, Caffeine, Aminophylline, 분해지방운반제인 L-carnitine 등을 사용한다. 상기 약물은 3-4 가지 약제를 혼합하여 동시에 투여한다Mesotherapy is a drug that promotes microcirculation, pentoxifylline, procain, buflomedil, calcitonine2, and improves water retention and edema.It uses caffein, dicynone, calcitonine, esberiven, thiomucase. As a drug to promote lipolysis, caffein, pentoxifylline, and calcitonine are used, and vit C, thiomucase, and conjonctil are used to improve connective tissue abnormalities. In addition, Lidocaine for local anesthesia, Ginkgo biloba for blood circulation, Buflomedil for blood circulation and lipolytic agents, Pentoxifylline, Caffeine, Aminophylline, and L-carnitine for decomposing fat are used. The drug is administered simultaneously by mixing 3-4 drugs
상기한 메조테라피시술은 표피나 진피층의 1-4mm 아래 부위인 피부중간층에 주사한다. 주 1-2 회 주사하며 4-6회면 셀룰라이트 개선효과가 나타난다. The mesotherapy procedure is injected into the interlayer of skin, 1-4 mm below the epidermis or dermis. Inject 1-2 times a week and 4-6 times to improve cellulite.
지방층은 비만정도와 부위에 따라 다르나 보통 9-13mm로 본다. 이 부분은 LLD주와 PPC주를 사용한다.The fat layer varies depending on the degree of obesity and area, but is usually viewed as 9-13mm. This part uses LLD and PPC strains.
LLD주는 지방세포를 일부 파괴하고 고여있는 지방과 관련된 물질을 빠르게 림프관으로 이동시켜 배출함으로써 전체적인 체형을 교정하여 준다. 혼합약물은 Hyaluronidase와 Lidocaine와 그리고 Pheniramine 을 각각 1cc씩 혼합한다. 부위별 4-6포인트 1포인트당 0.5-1.5cc를 5cm간격으로 주사하며, 주 2 -4회 시술한다.The LLD strain partially destroys fat cells and corrects the overall body shape by rapidly transporting accumulated fat-related substances into lymphatic vessels. The mixed drug is mixed with 1cc of Hyaluronidase, Lidocaine and Pheniramine. Inject 0.5-1.5cc at 5cm intervals per point for 4-6 points per site, and perform 2-4 times a week.
PPC주(phosphatidyleboline주 : lipodissolve주)는 지방흡입 수술하지 않고 비만 신체 지방층에 직접주사하여 지방세포 자체를 파괴하여 배출시키는 주사시술법이다. 일명 지방파괴주사로 불리우고 있다. 예를들어 복부 경우, 1-1.5cm간격으로 1지점당 0.5-1.0cc 로 20-100포인트 주사한다. 3주 내지 1달 간격으로 1-3 회 시술하며 시술전에 RF 행한다. PPC (phosphatidyleboline, lipodissolve) is an injection method that destroys and releases fat cells by directly injecting into the fat layer of obese body without liposuction. It is called a fat destruction injection. For example, in the abdomen, 20-100 points are injected at 0.5-1.0cc per point at intervals of 1-1.5 cm. The procedure is performed 1-3 times at intervals of 3 weeks to 1 month and RF is performed before the procedure.
예를들어, 20-30대 복부비만 경우, RF 10분, PPC, 캐비테이션(공동)(28키로헤르츠) 2 회 행하고, 30-50대 경우, 1주차는 RF 10분, LLD, 캐비테이션(공동)(28키로헤르츠) 행하고, 2 주차는 캐비테이션,PPC, RF를 행한다.For example, for 20-30's abdominal obesity, RF 10 minutes, PPC, cavitation (joint) twice (28 kHz), 30-30, week 1 RF 10 minutes, LLD, cavitation (co) (28 kHz) and 2 parking cavitation, PPC, RF.
다음, 카복시테라피(carbon dioxide therapy}는 1932년 프랑스에서 개발되어 당뇨환자의 족부궤양, 화상환자 피부재생, 건선환자 치료 등에 사용되어 오다가 2001년부터 부분지방감소 치료로 활용되어오고 있다. 치료 원리는 피하지방(QS)층에 액화이산화탄소를 100-2000cc 주입하면 선택적으로 지방조직이 팽창하면서 단단한 셀룰라이트 부분이 느슨하게 풀어지면서 지방세포에 얇은 균열 라인이 나타나고 세포 상이사이 공간에 중성지방(TG)이 방출되어 지방조직이 파열된다Next, carbon dioxide therapy was developed in France in 1932 and used to treat foot ulcers, burn skin regeneration and psoriasis in diabetics, and has been used to treat partial fat reduction since 2001. When 100-2000cc of liquefied carbon dioxide is injected into the subcutaneous fat (QS) layer, the adipose tissue expands and loosens the hard cellulite part, resulting in thin crack lines in the adipocytes and triglyceride (TG) in the spaces between the cells. Released and ruptures adipose tissue
액화이산화탄소는 혈관 등의 다른 조직에는 손상을 주지 않는다. 지방세포가 과팽창으로 물리적으로 지방이 일부 분해되고 흡수가 촉진된다(LYPOLYTIC 효과). 이와 함께 모세혈관의 일시적인 수축과 반사적 확장으로 미세순환이 향상되고 혈액량이 증가되면서 조직내 산소 운반이 증가하여 지방세포의 대사가 향상되어 분해된 지방(지방산, 글리세롤 등)과 노폐물 잉여수분들의 배출이 촉진된다Liquefied carbon dioxide does not damage other tissues such as blood vessels. Overexpansion of fat cells physically breaks down fat and promotes absorption (LYPOLYTIC effect). In addition, the microcirculation is improved due to the temporary contraction and reflexive expansion of capillaries, and the blood volume increases, the oxygen transport in tissue increases, and the metabolism of adipocytes is improved, resulting in the release of decomposed fat (fatty acid, glycerol, etc.) and waste excess water. Is promoted
주입된 이산화산소의 분압이 높아지면 산소 해리도가 증가되어 체내 유산소 효과도 가져오게되어 결과적으로 비만부위 사이즈 감소와 셀룰라이트를 치료하는 비만치료 효과를 얻게 된다Increasing the partial pressure of the injected oxygen dioxide increases oxygen dissociation, resulting in aerobic effects in the body, resulting in a reduction in the size of obesity and the treatment of obesity to treat cellulite.
부가적으로 진피층(DERMIS)에 콜라겐 섬유들이 재배열되면서 더 넓게 분포되면서 흉터, 튼살을 복원하고 탄력을 증대시키는 시너지 효과도 가져온다. 주입된 이산화탄소는 인체에 무해한 의료용 이산화탄소로 우리몸의 정상적인 호흡과정을 통해 자연스럽게 체외로 배출된다Additionally, as collagen fibers are rearranged in the dermis layer, they are more widely distributed, resulting in synergistic effects that restore scars, stretch marks and increase elasticity. The injected carbon dioxide is a medical carbon dioxide that is harmless to the human body and is naturally released into the body through the normal breathing process of our body.
치료 방법은 주 2-3 회, 1 부위당 5-10 분 분당 50-100cc 시술하며 최소 10 회 이상 시술시 효과가 있다. 통증 완화를 위해 시술전에 이산화 탄소를 체내 온도와 맞추어 따듯하게 하거나 시술 전 손 맛사지, 경직 부분 풀어 주기, 수술전 10 분간 고주파 , 온열 찜질팩, 바이브레이터 중 선택하여 행한다
Treatment is 2-3 times a week, 50-100cc per minute for 5-10 minutes per site, and is effective at least 10 times. In order to relieve pain, the carbon dioxide should be warmed up to the body temperature before the procedure, or hand massage before the procedure, stiffening of the stiffness part, or selected from high frequency, heat pack, or vibrator for 10 minutes before the procedure.
상기한 치료 방법과 장치를 이용하는 본 발명의 셀룰라이트 치료방법 구성은, 비만측정, 측정부위의 지방이완(분해준비), 지방분해, 분해된 지방 배출, 배출지방의 연소, 탄력향상으로 마무리된다The cellulite treatment method of the present invention using the above-described treatment method and apparatus is completed by measuring obesity, fat relaxation (preparation of fat) at the measurement site, lipolysis, discharging of broken fat, burning of discharged fat, and improving elasticity.
비만측정은 팔, 복부, 허벅지, 종아리, 전신 등을 측정한다. 예를들어 열화상카메라로는 전신, 팔, 복부, 허벅지, 종아리를 촬영하여 이미지로 표시한다Obesity measurement measures the arms, abdomen, thighs, calves, and the whole body. For example, a thermal imaging camera photographs the whole body, arms, abdomen, thighs and calves and displays them as images.
지방분해준비(지방 이완)는 지방을 둘러싸고 있는 섬유질을 분해하고 약한 혈관계를 원활하게 해 준다. 지방분해는 각 지방끼리의 연결고리를 끊어줌으로써 지방을 분해하고 약화시킨다. 이에 사용되는 장비는 RF 장비를 사용한다. 주파수 50-60 헤르츠, 출력주파수 0.3메가헤르츠인 RF 장비를 사용하여 얼굴에 시술할 경우엔 0.5메가헤르츠, 바디에 시술할 경우엔 0.3 메가헤르츠가 출력되게 사용한다
Lipolysis preparation (fat relaxation) breaks down the fibers surrounding fat and facilitates the weak vascular system. Lipolysis breaks down and weakens fat by breaking the links between fats. The equipment used for this uses RF equipment. When using RF equipment with a frequency of 50-60 hertz and an output frequency of 0.3 megahertz, 0.5 MHz is applied to the face and 0.3 MHz is applied to the body.
지방 분해는 이산화탄소 주입장비를 사용한 카복시테라피 방법을 사용하거나 또는 지방분해 약물 주사방법인 메조테라피 방법을 사용한다Lipolysis uses carboxytherapy with carbon dioxide injection or mesotherapy, a lipolytic drug injection method.
한가지 구체적인 예를들어, 카복시테라피방법은 이산화탄소 주입장비를 사용하여 50-60헤르츠 주파수를 사용하며 가스압은 2.5 바아, 가스출력은 10-800cc 이며, 주사기를 사용한 주입 전에 25 내지 35도로 히팅하여 통증이 적도록 한다. 얼굴 팔, 복부, 등, 허벅지, 종아리 등의 시술부위에 따라 액화이산화탄소 주입량을 분당 10-100cc, 주입시간은 5 내지 10분 시술한다In one specific example, the carboxytherapy method uses a carbon dioxide injection device using a frequency of 50-60 hertz, a gas pressure of 2.5 bar, a gas output of 10-800cc, and pain by heating 25 to 35 degrees before injection using a syringe. Write it down. Depending on the treatment area of the face, abdomen, back, thigh, calf, etc., the amount of liquefied carbon dioxide is injected at 10-100cc per minute, and the injection time is 5 to 10 minutes.
도 1 은 본 발명에 따른 카복시테라피 방법으로 시술한 결과이다1 is a result of the procedure by the carboxytherapy method according to the present invention
도시한 바와 같이, 이산화탄소 주입 전후의 피부 내부 조직 변화를 나타내고 있다. 도 2 는 동일한 방법으로 복부에 대한 시술 전후 사진을 나타낸다As shown, the internal tissue changes in skin before and after the injection of carbon dioxide are shown. Figure 2 shows a photograph before and after the procedure for the abdomen in the same way
지방 배출 운반은 분해된 지방을 림프계와 혈관계로 배출시키고 막혀 있는 혈관 순환계를 치료하며 그 흐름을 원활하게 하여 준다. 즉 외부적 압력이나 전기적 자극을 통하여 체외로 배출 유도한다. Fat excretion transport releases the degraded fat into the lymphatic and vascular systems, treats clogged vascular circulatory systems, and facilitates their flow. In other words, the discharge to the body through external pressure or electrical stimulation.
사용되는 장비는 예를 들어, 도 3 에 도시한 흡입기구(1)를 사용한다The equipment used uses the suction mechanism 1 shown in FIG. 3, for example.
흡입기구(1)는 하부에 롤러(2)가 2 개 형성되고 그 사이에 흡입공(3)이 형성되어 흡입한다. 롤러(2)는 피부(4)를 잡아 주는 역할을 하여, 음압에 의해 흡입이 흡입공(3)에서 이루어지면 피부(4)가 흡입되어 올라간다. 이러한 상태로 흡입기구(1)를 이동시켜주면서 시술한다. 그러면 피부, 지방 및 근육에 대한 강력하고 부드러운 압력을 주어서 지방의 운반과 배출을 돕는다
The suction mechanism 1 is provided with two
그리고 액화되어 배출된 지방을 혈액순환과 근육질에서 연소시키는 단계로 2-3일 내에 연소시키지 않으면 다시 지방세포로 고체화된다. 지방 연소단계는 저주파장비를 사용하며, 자극주파수 5-120 헤르츠의 장비를 사용한다. 이는 전극에 의한 자극으로 지방을 파괴 분해하여 연소시킨다Then, the liquefied and discharged fat is burned in the blood circulation and muscles. If it is not burned within 2-3 days, it solidifies into fat cells. The fat burning stage uses low frequency equipment and equipment with a stimulation frequency of 5-120 hertz. It destroys and burns fat by stimulation by electrodes.
마지막으로 지방 배출 후 피부가 이완되므로 피부에 탄력을 주는 탄력 향상을 위한 시술은 지방 이완시 사용하였던 RF 장비를 사용하며, 상술한 바와 같이 출력주파수는 0.3 메가헤르츠이다
Finally, since the skin is relaxed after fat discharge, the procedure for improving elasticity to give elasticity to the skin uses RF equipment used at the time of fat relaxation. As described above, the output frequency is 0.3 megahertz.
1 흡입기구 2 롤러
3 흡입공 4 피부1
3 suction hole 4 skin
Claims (5)
신체의 팔, 복부, 허벅지, 종아리, 전신의 비만 부위를 측정하는 단계;
측정된 비만 부위의 지방분해를 위해, 지방을 둘러싸고 있는 섬유질을 분해하고 지방끼리의 연결고리를 끊어줌으로써 지방을 분해하고 약화시키는 이완 처리하는 단계;
비만 부위를 액화이산화탄소를 주사하거나 또는 지방분해 약물을 주사하는 방법 중 어느 하나를 사용하여 지방조직을 분해하는 단계;
분해된 지방을 배출하기 위해, 피부, 지방 및 근육에 대한 강력하고 부드러운 압력을 주어서 지방의 운반과 배출을 돕도록 하는 해체되어 액화된 지방의 배출 단계;
액화되어 배출된 지방을 혈액순환과정과 근육질에서 연소시키기 위해 저주파장비를 사용하여, 전극에 의한 자극으로 지방을 연소시키는 지방연소 단계;
지방이 제거된 비만 부위의 피부 탄력을 향상시키는 단계를 포함하는 것을 특징으로 하는 셀룰라이트 교정방법In the cellulite correction method,
Measuring obesity in the arms, abdomen, thighs, calves and whole body of the body;
For lipolysis of the measured obesity site, a step of relaxation to break down and weaken fat by breaking down the fiber surrounding the fat and breaking the link between the fat;
Degrading adipose tissue using any of the methods of injecting liquefied carbon dioxide or a lipolytic drug into the obese site;
Discharging the disintegrated and liquefied fat to give strong and gentle pressure to the skin, fat and muscle to assist in the transport and release of fat to release the degraded fat;
A fat burning step of burning fat by stimulation by an electrode, using low frequency equipment to burn the liquefied and discharged fat in the blood circulation and muscle;
Cellulite correction method comprising the step of improving the skin elasticity of the fat is removed obesity
상기한 지방분해를 위해 지방을 이완처리하는 단계는 고주파 또는 중저파의 초음파 자극장치를 이용하여 지방조직을 이완시키는 것을 특징으로 하는 셀룰라이트 교정방법The method of claim 1,
The step of relaxing the fat for lipolysis is a cellulite correction method, characterized in that to relax the fat tissue using an ultrasonic stimulation apparatus of high frequency or low frequency
미세혈액순환을 촉진하는 약물로, pentoxifylline, procain, buflomedil, calcitonine2,
수분저류와 부종을 개선하는 약물로, caffein, dicynone, calcitonine, esberiven, thiomucase,
지방분해를 촉진하는 약물로, caffein, pentoxifylline, calcitonine,
결합조직의 이상을 개선하는 약물로 vit C, thiomucase, conjonctil,
국소마취용인 Lidocaine,
혈액순환촉진제인 Ginkgo biloba,
혈액순환촉진 및 지방분해제인 Buflomedil,
지방분해제인 Pentoxifylline, Caffeine, Aminophylline,
분해지방운반제인 L-carnitine 중 3-4 가지 약제를 혼합하여 투여하는 것을 특징으로 하는 셀룰라이트 교정방법According to claim 1, wherein the drug used in the step of decomposing adipose tissue by injection of the obesity site,
Drugs that promote microcirculation, such as pentoxifylline, procain, buflomedil, calcitonine2,
Drugs that improve water retention and edema, such as caffein, dicynone, calcitonine, esberiven, thiomucase,
Drugs that promote lipolysis, such as caffein, pentoxifylline, calcitonine,
Drugs that improve abnormalities of connective tissue include vit C, thiomucase, conjonctil,
Lidocaine for local anesthesia,
Ginkgo biloba, a blood circulation promoter
Buflomedil, a blood circulation promoting and lipolytic agent,
Lipolytic agents Pentoxifylline, Caffeine, Aminophylline,
Cellulite correction method characterized by administering a mixture of 3-4 drugs in L-carnitine, a breakdown fat transporter
상기한 해체된 지방을 배출시키는 단계는, 하부에 롤러(2)가 구성되고 롤러(2) 사이에는 흡입공(3)을 갖춘 흡입기구(1)를 사용하여, 시술된 비만부위 피부 표면을 흡입시키면서 롤러(2)를 이동시키는 방법으로 실시하는 것을 특징으로 하는 셀룰라이트 교정방법The method of claim 1,
In the step of discharging the disintegrated fat, using the suction mechanism (1) having a roller (2) in the lower portion and the suction hole (3) between the rollers 2, suctioning the skin surface of the obese area Cellulite correction method characterized in that carried out by moving the roller 2 while
배출된 지방을 연소시키는 단계는, 5 내지 120 헤르츠의 저주파 장치를 이용하여 피부 표면에 대하여 전기 자극을 실시하는 것을 특징으로 하는 셀룰라이트 교정방법
The method of claim 1,
Burning the discharged fat, cellulite correction method, characterized in that the electrical stimulation to the surface of the skin using a low-frequency device of 5 to 120 Hertz
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110064727A KR20130003394A (en) | 2011-06-30 | 2011-06-30 | Correction method of cellulite |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110064727A KR20130003394A (en) | 2011-06-30 | 2011-06-30 | Correction method of cellulite |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20130003394A true KR20130003394A (en) | 2013-01-09 |
Family
ID=47835629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110064727A KR20130003394A (en) | 2011-06-30 | 2011-06-30 | Correction method of cellulite |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20130003394A (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101706549B1 (en) | 2016-09-09 | 2017-02-14 | 손유나 | Injection composition comprising hyaluronidase for Local Fat Reduction |
KR20170101081A (en) | 2016-02-25 | 2017-09-05 | 오명진 | Parenteral solution for diet containing lipolysis and celluite-improoving ingredient |
CN107362446A (en) * | 2016-05-13 | 2017-11-21 | 基替基悦尼斯株式会社 | Portable middle low frequency muscular movement equipment |
KR102005752B1 (en) | 2019-04-17 | 2019-07-31 | 손유나 | Injection composition comprising hyaluronidase for Rmoving Local Fat |
KR102010369B1 (en) | 2018-02-13 | 2019-08-13 | 강은희 | Injectable composition for celluite-improving |
KR20190103746A (en) | 2018-02-28 | 2019-09-05 | 강은희 | Apparatus and medical procedure for cellulite improving |
KR20200029113A (en) * | 2018-09-08 | 2020-03-18 | 이윤택 | Apple hip cushion device to remove cellulite |
KR20200084814A (en) | 2020-03-27 | 2020-07-13 | 주식회사 미라클강남 | Composition for lipolysis and cellulite improvement, and the kit comprising the same |
KR102145376B1 (en) | 2020-06-01 | 2020-08-18 | 박건환 | Injection Composition Comprising for Local Fat Reduction Including Choline alfoscerate |
KR102195330B1 (en) | 2020-08-26 | 2020-12-28 | 공주명 | Injection composition for local fat reduction |
KR20210046097A (en) * | 2019-10-17 | 2021-04-28 | 최보윤 | Composition for lipolysis and injection apparatus thereof |
WO2024048872A1 (en) * | 2022-09-01 | 2024-03-07 | 홍종철 | Contour injection composition |
-
2011
- 2011-06-30 KR KR1020110064727A patent/KR20130003394A/en not_active Application Discontinuation
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170101081A (en) | 2016-02-25 | 2017-09-05 | 오명진 | Parenteral solution for diet containing lipolysis and celluite-improoving ingredient |
KR20180064362A (en) | 2016-02-25 | 2018-06-14 | 오명진 | A diet injectable composition containing an improved component of cellulite and an antioxidant active ingredient, a decrease in edema and a relieving component of pain |
CN107362446A (en) * | 2016-05-13 | 2017-11-21 | 基替基悦尼斯株式会社 | Portable middle low frequency muscular movement equipment |
KR101706549B1 (en) | 2016-09-09 | 2017-02-14 | 손유나 | Injection composition comprising hyaluronidase for Local Fat Reduction |
KR102010369B1 (en) | 2018-02-13 | 2019-08-13 | 강은희 | Injectable composition for celluite-improving |
KR20190103746A (en) | 2018-02-28 | 2019-09-05 | 강은희 | Apparatus and medical procedure for cellulite improving |
KR20200029113A (en) * | 2018-09-08 | 2020-03-18 | 이윤택 | Apple hip cushion device to remove cellulite |
KR102005752B1 (en) | 2019-04-17 | 2019-07-31 | 손유나 | Injection composition comprising hyaluronidase for Rmoving Local Fat |
KR20210046097A (en) * | 2019-10-17 | 2021-04-28 | 최보윤 | Composition for lipolysis and injection apparatus thereof |
KR20200084814A (en) | 2020-03-27 | 2020-07-13 | 주식회사 미라클강남 | Composition for lipolysis and cellulite improvement, and the kit comprising the same |
KR102145376B1 (en) | 2020-06-01 | 2020-08-18 | 박건환 | Injection Composition Comprising for Local Fat Reduction Including Choline alfoscerate |
KR102195330B1 (en) | 2020-08-26 | 2020-12-28 | 공주명 | Injection composition for local fat reduction |
WO2024048872A1 (en) * | 2022-09-01 | 2024-03-07 | 홍종철 | Contour injection composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20130003394A (en) | Correction method of cellulite | |
KR101706549B1 (en) | Injection composition comprising hyaluronidase for Local Fat Reduction | |
DK1603507T3 (en) | ULTRASONIC TREATMENT OF CELLULITIS | |
US11324673B2 (en) | Cosmetic appearance of skin | |
US20090048555A1 (en) | Drug delivery system | |
KR20090111916A (en) | Pharmaceutical preparation for removing local body fat | |
Zhang et al. | Clinical arterial infusion of calcium gluconate: the preferred method for treating hydrofluoric acid burns of distal human limbs | |
Choi et al. | Edema and pain reduction using transcutaneous electrical nerve stimulation treatment | |
US20070100402A1 (en) | Fat reduction using external laser radiation and niacin | |
RU2385169C1 (en) | Method of treating children with posttraumatic limb injures in postoperative period | |
EP2645954A1 (en) | Apparatus for the treatment of hyperhidrosis | |
RU2576788C1 (en) | Method of complex restoration and maintenance of the skin, subcutaneous fat, muscle and connective tissue in cosmetology (optional) | |
Alizadeh et al. | Non-invasive Body Contouring Technologies: An Updated Narrative Review | |
AKRAM et al. | Ultrasound cavitation versus cryolipolysis on central obese patients | |
CN201542976U (en) | Novel black plaster with acupuncture point therapeutic function | |
Majani et al. | Tissue mechanostimulation in the treatment of scars | |
WO2006007675A1 (en) | Cholic acid and/or its derivatives for the reduction of localized fat in the human body | |
CN203524960U (en) | Fumigation type meibomian gland massager | |
Roberts | Transdermal drug delivery using iontophoresis and phonophoresis | |
Sankaran et al. | A Comprehensive Study on Design of Frequency Probe for Treatment of Plantar Corns and Warts using Microwave Technology | |
US10765598B2 (en) | Negative pressure device and methods thereof | |
CN110200764A (en) | A kind of combined type dialysis nursing bed | |
KR102335712B1 (en) | Composition for lipolysis and injection apparatus thereof | |
RU2747423C1 (en) | Method for treatment of complications of contour plastic surgery | |
RU2698011C1 (en) | Method of treating burns by ultrasonic oscillations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal |